パルボシクリブ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "パルボシクリブ" in Japanese language version.

refsWebsite

Global rank Japanese rank

24nih.gov

4^th place

24^th place

12doi.org

2^nd place

6^th place

3pfizer.com

low place

3fda.gov

447^th place

1,043^rd place

2worldcat.org

5^th place

19^th place

2jefferson.edu

low place

2nytimes.com

7^th place

63^rd place

2cancer.gov

1,684^th place

6,245^th place

2nice.org.uk

3,258^th place

1,755^th place

1onclive.com

low place

1seekingalpha.com

5,344^th place

low place

1europa.eu

68^th place

425^th place

1bbc.com

20^th place

100^th place

1mixonline.jp

low place

4,576^th place

1oncolo.jp

low place

1yahoo.com

38^th place

203^rd place

1aacr.org

low place

1web.archive.org

1^st place

1businesswire.com

615^th place

1,955^th place

1dailymail.co.uk

219^th place

241^st place

1forbes.com

54^th place

269^th place

1reuters.com

49^th place

67^th place

1g1therapeutics.com

low place

aacr.org

Palbociclib Shows Promising Results in Patients With Hormone Receptor-positive Metastatic Breast Cancer Archived 2014-04-08 at the Wayback Machine., AACR in the News, April 6, 2014

bbc.com

“Breast cancer drug approved for NHS use” (英語). BBC News. (2017年12月11日) 2017年12月11日閲覧。

businesswire.com

https://www.businesswire.com/news/home/20200529005610/en/Pfizer-Update-Phase-3-PALLAS-Trial-IBRANCE%C2%AE

cancer.gov

“Intervention Dynamic Trial Listing Page” (英語). National Cancer Institute. 2017年12月16日閲覧。
“NCI Drug Dictionary”. National Cancer Institute (2011年2月2日). 2017年12月16日閲覧。

dailymail.co.uk

“Pfizer breast cancer drug gets early FDA approval”. Daily Mail. Associated Press (London). (3 February 2015) 2 November 2015閲覧。

doi.org

Finn, RS; Dering, J; Conklin, D; Kalous, O; Cohen, DJ; Desai, AJ; Ginther, C; Atefi, M et al. (2009). “PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro”. Breast Cancer Research 11 (5): R77. doi:10.1186/bcr2419. PMC 2790859. PMID 19874578.
“Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer”. Expert Opin Pharmacother 15 (3): 407–20. (2014). doi:10.1517/14656566.2014.870555. PMID 24369047.
Xu, Hanxiao; Yu, Shengnan; Liu, Qian; Yuan, Xun; Mani, Sridhar; Pestell, Richard G.; Wu, Kongming (2017-04-24). “Recent advances of highly selective CDK4/6 inhibitors in breast cancer”. Journal of Hematology & Oncology 10 (1): 97. doi:10.1186/s13045-017-0467-2. ISSN 1756-8722. PMC 5404666. PMID 28438180.
Finn (November 17, 2016). “Palbociclib and Letrozole in Advanced Breast Cancer”. New England Journal of Medicine 375 (20): 1925–1936. doi:10.1056/NEJMoa1607303. PMID 27959613.
Turner, Nicholas C.; Ro, Jungsil; André, Fabrice; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Loibl, Sibylle et al. (2015-07-16). “Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer”. New England Journal of Medicine 373 (3): 209–219. doi:10.1056/NEJMoa1505270. ISSN 0028-4793. PMID 26030518.
Turner, Nicholas C.; Slamon, Dennis J.; Ro, Jungsil; Bondarenko, Igor; Im, Seock-Ah; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela et al. (15 November 2018). “Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer”. New England Journal of Medicine 379 (20): 1926–1936. doi:10.1056/nejmoa1810527. PMID 30345905.
Portman, Neil; Alexandrou, Sarah; Carson, Emma; Wang, Shudong; Lim, Elgene; Caldon, C Elizabeth (January 2019). “Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer”. Endocrine-Related Cancer 26 (1): R15–R30. doi:10.1530/erc-18-0317. PMID 30389903.
Guarducci, Cristina; Bonechi, Martina; Boccalini, Giulia; Benelli, Matteo; Risi, Emanuela; Di Leo, Angelo; Malorni, Luca; Migliaccio, Ilenia (2017). “Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response”. Breast Care 12 (5): 304–308. doi:10.1159/000484167. PMC 5704709. PMID 29234249.
Li, Zhiqiang; Razavi, Pedram; Li, Qing; Toy, Weiyi; Liu, Bo; Ping, Christina; Hsieh, Wilson; Sanchez-Vega, Francisco et al. (December 2018). “Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway”. Cancer Cell 34 (6): 893–905.e8. doi:10.1016/j.ccell.2018.11.006. PMC 6294301. PMID 30537512.
Turner, Nicholas C.; Ro, Jungsil; André, Fabrice; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Loibl, Sibylle et al. (16 July 2015). “Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer”. New England Journal of Medicine 373 (3): 209–219. doi:10.1056/nejmoa1505270. PMID 26030518.
Cornell, Liam; Wander, Seth A.; Visal, Tanvi; Wagle, Nikhil; Shapiro, Geoffrey I. (March 2019). “MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance”. Cell Reports 26 (10): 2667–2680.e7. doi:10.1016/j.celrep.2019.02.023. PMC 6449498. PMID 30840889.
McCartney, Amelia; Migliaccio, Ilenia; Bonechi, Martina; Biagioni, Chiara; Romagnoli, Dario; De Luca, Francesca; Galardi, Francesca; Risi, Emanuela et al. (23 July 2019). “Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice”. Frontiers in Oncology 9: 666. doi:10.3389/fonc.2019.00666. PMC 6664013. PMID 31396487.

europa.eu

ema.europa.eu

Ibrance (palbociclib) European public assessment report

fda.gov

“Palbociclib (Ibrance)”. FDA (2017年3月31日). 2020年6月2日閲覧。
Research. “Approved Drugs - Palbociclib (IBRANCE)” (英語). www.fda.gov. 2017年12月16日閲覧。

accessdata.fda.gov

“IBRANCE FDA Drug Label”. 2017年12月15日閲覧。

forbes.com

Herper, Matthew (19 February 2010), “The World's Most Expensive Drugs”, Forbes 25 June 2015閲覧。

g1therapeutics.com

“G1T28”. G1 Therapeutics. 2017年12月16日閲覧。

jefferson.edu

jdc.jefferson.edu

Turner, Nicholas C.; Ro, Jungsil; André, Fabrice; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Loibl, Sibylle et al. (2015-07-16). “Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer”. New England Journal of Medicine 373 (3): 209–219. doi:10.1056/NEJMoa1505270. ISSN 0028-4793. PMID 26030518.
Turner, Nicholas C.; Ro, Jungsil; André, Fabrice; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Loibl, Sibylle et al. (16 July 2015). “Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer”. New England Journal of Medicine 373 (3): 209–219. doi:10.1056/nejmoa1505270. PMID 26030518.

mixonline.jp

“ファイザー　新規の乳がん治療薬イブランスを新発売　世界初のCDK4/6阻害薬”. ミクスonline (2017年12月18日). 2020年6月2日閲覧。

nice.org.uk

nih.gov

pubmed.ncbi.nlm.nih.gov

Finn, RS; Dering, J; Conklin, D; Kalous, O; Cohen, DJ; Desai, AJ; Ginther, C; Atefi, M et al. (2009). “PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro”. Breast Cancer Research 11 (5): R77. doi:10.1186/bcr2419. PMC 2790859. PMID 19874578.
“Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer”. Expert Opin Pharmacother 15 (3): 407–20. (2014). doi:10.1517/14656566.2014.870555. PMID 24369047.
Xu, Hanxiao; Yu, Shengnan; Liu, Qian; Yuan, Xun; Mani, Sridhar; Pestell, Richard G.; Wu, Kongming (2017-04-24). “Recent advances of highly selective CDK4/6 inhibitors in breast cancer”. Journal of Hematology & Oncology 10 (1): 97. doi:10.1186/s13045-017-0467-2. ISSN 1756-8722. PMC 5404666. PMID 28438180.
Finn (November 17, 2016). “Palbociclib and Letrozole in Advanced Breast Cancer”. New England Journal of Medicine 375 (20): 1925–1936. doi:10.1056/NEJMoa1607303. PMID 27959613.
Turner, Nicholas C.; Ro, Jungsil; André, Fabrice; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Loibl, Sibylle et al. (2015-07-16). “Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer”. New England Journal of Medicine 373 (3): 209–219. doi:10.1056/NEJMoa1505270. ISSN 0028-4793. PMID 26030518.
Turner, Nicholas C.; Slamon, Dennis J.; Ro, Jungsil; Bondarenko, Igor; Im, Seock-Ah; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela et al. (15 November 2018). “Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer”. New England Journal of Medicine 379 (20): 1926–1936. doi:10.1056/nejmoa1810527. PMID 30345905.
Portman, Neil; Alexandrou, Sarah; Carson, Emma; Wang, Shudong; Lim, Elgene; Caldon, C Elizabeth (January 2019). “Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer”. Endocrine-Related Cancer 26 (1): R15–R30. doi:10.1530/erc-18-0317. PMID 30389903.
Guarducci, Cristina; Bonechi, Martina; Boccalini, Giulia; Benelli, Matteo; Risi, Emanuela; Di Leo, Angelo; Malorni, Luca; Migliaccio, Ilenia (2017). “Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response”. Breast Care 12 (5): 304–308. doi:10.1159/000484167. PMC 5704709. PMID 29234249.
Li, Zhiqiang; Razavi, Pedram; Li, Qing; Toy, Weiyi; Liu, Bo; Ping, Christina; Hsieh, Wilson; Sanchez-Vega, Francisco et al. (December 2018). “Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway”. Cancer Cell 34 (6): 893–905.e8. doi:10.1016/j.ccell.2018.11.006. PMC 6294301. PMID 30537512.
Turner, Nicholas C.; Ro, Jungsil; André, Fabrice; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Loibl, Sibylle et al. (16 July 2015). “Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer”. New England Journal of Medicine 373 (3): 209–219. doi:10.1056/nejmoa1505270. PMID 26030518.
Cornell, Liam; Wander, Seth A.; Visal, Tanvi; Wagle, Nikhil; Shapiro, Geoffrey I. (March 2019). “MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance”. Cell Reports 26 (10): 2667–2680.e7. doi:10.1016/j.celrep.2019.02.023. PMC 6449498. PMID 30840889.
McCartney, Amelia; Migliaccio, Ilenia; Bonechi, Martina; Biagioni, Chiara; Romagnoli, Dario; De Luca, Francesca; Galardi, Francesca; Risi, Emanuela et al. (23 July 2019). “Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice”. Frontiers in Oncology 9: 666. doi:10.3389/fonc.2019.00666. PMC 6664013. PMID 31396487.

ncbi.nlm.nih.gov

Finn, RS; Dering, J; Conklin, D; Kalous, O; Cohen, DJ; Desai, AJ; Ginther, C; Atefi, M et al. (2009). “PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro”. Breast Cancer Research 11 (5): R77. doi:10.1186/bcr2419. PMC 2790859. PMID 19874578.
Xu, Hanxiao; Yu, Shengnan; Liu, Qian; Yuan, Xun; Mani, Sridhar; Pestell, Richard G.; Wu, Kongming (2017-04-24). “Recent advances of highly selective CDK4/6 inhibitors in breast cancer”. Journal of Hematology & Oncology 10 (1): 97. doi:10.1186/s13045-017-0467-2. ISSN 1756-8722. PMC 5404666. PMID 28438180.
Guarducci, Cristina; Bonechi, Martina; Boccalini, Giulia; Benelli, Matteo; Risi, Emanuela; Di Leo, Angelo; Malorni, Luca; Migliaccio, Ilenia (2017). “Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response”. Breast Care 12 (5): 304–308. doi:10.1159/000484167. PMC 5704709. PMID 29234249.
Li, Zhiqiang; Razavi, Pedram; Li, Qing; Toy, Weiyi; Liu, Bo; Ping, Christina; Hsieh, Wilson; Sanchez-Vega, Francisco et al. (December 2018). “Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway”. Cancer Cell 34 (6): 893–905.e8. doi:10.1016/j.ccell.2018.11.006. PMC 6294301. PMID 30537512.
Cornell, Liam; Wander, Seth A.; Visal, Tanvi; Wagle, Nikhil; Shapiro, Geoffrey I. (March 2019). “MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance”. Cell Reports 26 (10): 2667–2680.e7. doi:10.1016/j.celrep.2019.02.023. PMC 6449498. PMID 30840889.
McCartney, Amelia; Migliaccio, Ilenia; Bonechi, Martina; Biagioni, Chiara; Romagnoli, Dario; De Luca, Francesca; Galardi, Francesca; Risi, Emanuela et al. (23 July 2019). “Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice”. Frontiers in Oncology 9: 666. doi:10.3389/fonc.2019.00666. PMC 6664013. PMID 31396487.

pmc.ncbi.nlm.nih.gov

Finn, RS; Dering, J; Conklin, D; Kalous, O; Cohen, DJ; Desai, AJ; Ginther, C; Atefi, M et al. (2009). “PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro”. Breast Cancer Research 11 (5): R77. doi:10.1186/bcr2419. PMC 2790859. PMID 19874578.
Xu, Hanxiao; Yu, Shengnan; Liu, Qian; Yuan, Xun; Mani, Sridhar; Pestell, Richard G.; Wu, Kongming (2017-04-24). “Recent advances of highly selective CDK4/6 inhibitors in breast cancer”. Journal of Hematology & Oncology 10 (1): 97. doi:10.1186/s13045-017-0467-2. ISSN 1756-8722. PMC 5404666. PMID 28438180.
Guarducci, Cristina; Bonechi, Martina; Boccalini, Giulia; Benelli, Matteo; Risi, Emanuela; Di Leo, Angelo; Malorni, Luca; Migliaccio, Ilenia (2017). “Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response”. Breast Care 12 (5): 304–308. doi:10.1159/000484167. PMC 5704709. PMID 29234249.
Li, Zhiqiang; Razavi, Pedram; Li, Qing; Toy, Weiyi; Liu, Bo; Ping, Christina; Hsieh, Wilson; Sanchez-Vega, Francisco et al. (December 2018). “Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway”. Cancer Cell 34 (6): 893–905.e8. doi:10.1016/j.ccell.2018.11.006. PMC 6294301. PMID 30537512.
Cornell, Liam; Wander, Seth A.; Visal, Tanvi; Wagle, Nikhil; Shapiro, Geoffrey I. (March 2019). “MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance”. Cell Reports 26 (10): 2667–2680.e7. doi:10.1016/j.celrep.2019.02.023. PMC 6449498. PMID 30840889.
McCartney, Amelia; Migliaccio, Ilenia; Bonechi, Martina; Biagioni, Chiara; Romagnoli, Dario; De Luca, Francesca; Galardi, Francesca; Risi, Emanuela et al. (23 July 2019). “Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice”. Frontiers in Oncology 9: 666. doi:10.3389/fonc.2019.00666. PMC 6664013. PMID 31396487.

nytimes.com

Breast Cancer Drug Shows ‘Groundbreaking’ Results By ANDREW POLLACK, APRIL 6, 2014
Thomas, Kate (15 July 2015). “Specialty Pharmacies Proliferate, Along With Questions”. New York Times. 5 October 2015閲覧。

onclive.com

“FDA Approves Palbociclib for Metastatic Breast Cancer”. OncLive (3 Feb 2015). 2020年6月2日閲覧。

oncolo.jp

“乳がん治療薬イブランスに錠剤が登場－ファイザーー新剤形でより簡便な処方・服用の実現へー”. オンコロ (2020年1月23日). 2020年6月2日閲覧。

pfizer.com

reuters.com

“UK agency says Pfizer breast cancer drug too expensive”. Reuters. (3 February 2017) 2017年12月16日閲覧。

seekingalpha.com

Late-stage study of expanded use of Pfizer's Ibrance successful; global regulatory applications to follow. April 2016

web.archive.org

Palbociclib Shows Promising Results in Patients With Hormone Receptor-positive Metastatic Breast Cancer Archived 2014-04-08 at the Wayback Machine., AACR in the News, April 6, 2014

worldcat.org

search.worldcat.org

Xu, Hanxiao; Yu, Shengnan; Liu, Qian; Yuan, Xun; Mani, Sridhar; Pestell, Richard G.; Wu, Kongming (2017-04-24). “Recent advances of highly selective CDK4/6 inhibitors in breast cancer”. Journal of Hematology & Oncology 10 (1): 97. doi:10.1186/s13045-017-0467-2. ISSN 1756-8722. PMC 5404666. PMID 28438180.
Turner, Nicholas C.; Ro, Jungsil; André, Fabrice; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Loibl, Sibylle et al. (2015-07-16). “Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer”. New England Journal of Medicine 373 (3): 209–219. doi:10.1056/NEJMoa1505270. ISSN 0028-4793. PMID 26030518.

yahoo.com

news.yahoo.com

Beasley, Deena (6 April 2014). “Pfizer drug doubles time to breast cancer tumor growth in trial”. Reuters. Yahoo! News 7 April 2014閲覧。